[Retroperitoneal Fibrosis: Development of a Biomarker Profile for Diagnosis and Therapy Monitoring]

Overview

Journal Urologe A

Specialty Urology

Date 2014 Dec 16

PMID 25503722

Citations 3

Authors

S Kukuk

A Kretschmer

H Bruck

S Roth

A S Brandt

Affiliations

Soon will be listed here.

Abstract

Introduction: Retroperitoneal fibrosis (RPF) is a rare chronic inflammatory disease which is characterized by fibrotic tissue in the retroperitoneal space. There have only been a few studies on serum markers of this disease. The main goal of the current investigation was to identify biological markers which are increased in the serum of patients suffering from RPF and which may correlate with the extent of fibrosis.

Material And Methods: The serum of 42 patients with primary and yet untreated retroperitoneal fibrosis was examined for biomarkers known to be specific for fibrotic diseases and compared to a control group. In addition, patients were stratified according to the extent and volume of the retroperitoneal mass using cross-sectional imaging. To estimate the discriminatory power of the evaluated biomarkers, receiver operating characteristic (ROC) curves were created.

Results: Independent of the extent of fibrosis, calprotectin, fibrinogen, osteopontin, matrix metallopeptidase 9 (MMP-9), tenascin C and TIMP metallopeptidase inhibitor 1 (TIMP-1) were significantly increased (p<0.01) in patients suffering from RPF compared to the control group. Connective tissue growth factor (CTGF) was significantly elevated (p<0.01) in patients with high RPF burden only but monocyte chemoattractant protein 1 (MCP-1) and heart-type fatty acid binding protein (H-FABP) showed no increase in serum levels. The discriminatory power of these parameters was ranked by the ROC analysis which demonstrated an area under the curve (AUC) >0.87 for MMP-9, TIMP-1, osteopontin, tenascin C, asymmetric dimethylarginine (ADMA), fibrinogen and calprotectin and an AUC <0.64 for MMP-2, CTGF, H-FABP and MCP-1.

Conclusion: Several biomarkers of fibrogenesis were significantly elevated in patients suffering from RPF as compared to a control group. These biomarker candidates will be further evaluated for their potential to allow a differentiation between other diseases or if they could be used for disease monitoring.

Citing Articles

Genetic and Epidemiological Similarities, and Differences Between Postoperative Intraperitoneal Adhesion Development and Other Benign Fibro-proliferative Disorders.

Awonuga A, Chatzicharalampous C, Thakur M, Rambhatla A, Qadri F, Awonuga M Reprod Sci. 2021; 29(11):3055-3077.

PMID: 34515982 DOI: 10.1007/s43032-021-00726-9.

[New (and old) aspects of retroperitoneal fibrosis].

Brandt A, Dreger N, Muller E, Kukuk S, Roth S Urologe A. 2017; 56(7):887-894.

PMID: 28643106 DOI: 10.1007/s00120-017-0428-y.

[Diagnosis and treatment of retroperitoneal fibrosis].

Brandt A, Kukuk S, Dreger N, Muller E, Roth S Urologe A. 2016; 55(6):732-40.

PMID: 27168039 DOI: 10.1007/s00120-016-0081-x.

References

Lorenzen J, Kramer R, Kliem V, Bode-Boeger S, Veldink H, Haller H . Circulating levels of osteopontin are closely related to glomerular filtration rate and cardiovascular risk markers in patients with chronic kidney disease. Eur J Clin Invest. 2010; 40(4):294-300. DOI: 10.1111/j.1365-2362.2010.02271.x. View

Magrey M, Husni M, Kushner I, Calabrese L . Do acute-phase reactants predict response to glucocorticoid therapy in retroperitoneal fibrosis?. Arthritis Rheum. 2009; 61(5):674-9. DOI: 10.1002/art.24461. View

Milting H, Ellinghaus P, Seewald M, Cakar H, Bohms B, Kassner A . Plasma biomarkers of myocardial fibrosis and remodeling in terminal heart failure patients supported by mechanical circulatory support devices. J Heart Lung Transplant. 2008; 27(6):589-96. DOI: 10.1016/j.healun.2008.02.018. View

Vaglio A, Corradi D, Manenti L, Ferretti S, Garini G, Buzio C . Evidence of autoimmunity in chronic periaortitis: a prospective study. Am J Med. 2003; 114(6):454-62. DOI: 10.1016/s0002-9343(03)00056-1. View

Brandt A, Kamper L, Kukuk S, Haage P, Roth S . Associated findings and complications of retroperitoneal fibrosis in 204 patients: results of a urological registry. J Urol. 2010; 185(2):526-31. DOI: 10.1016/j.juro.2010.09.105. View

Zakrzewicz D, Eickelberg O . From arginine methylation to ADMA: a novel mechanism with therapeutic potential in chronic lung diseases. BMC Pulm Med. 2009; 9:5. PMC: 2637832. DOI: 10.1186/1471-2466-9-5. View

Parums D, Brown D, Mitchinson M . Serum antibodies to oxidized low-density lipoprotein and ceroid in chronic periaortitis. Arch Pathol Lab Med. 1990; 114(4):383-7. View

Kollert F, Binder M, Probst C, Uhl M, Zirlik A, Kayser G . CCL18 -- potential biomarker of fibroinflammatory activity in chronic periaortitis. J Rheumatol. 2012; 39(7):1407-12. DOI: 10.3899/jrheum.111143. View

Binder M, Christoph S, Sehnert B, Uhl M, Peter H, Voll R . Elevated serum osteopontin levels in idiopathic retroperitoneal fibrosis. Clin Exp Rheumatol. 2012; 30(5):772-5. View

10.

Kihara M, Sugihara T, Hosoya T, Miyasaka N . Clinical significance of complement as a biomarker of disease activity in 4 cases of IgG4-related disease with retroperitoneal fibrosis. Clin Exp Rheumatol. 2013; 31(6):947-9. View

11.

Abraham D . Connective tissue growth factor: growth factor, matricellular organizer, fibrotic biomarker or molecular target for anti-fibrotic therapy in SSc?. Rheumatology (Oxford). 2008; 47 Suppl 5:v8-9. DOI: 10.1093/rheumatology/ken278. View

12.

Midwood K, Hussenet T, Langlois B, Orend G . Advances in tenascin-C biology. Cell Mol Life Sci. 2011; 68(19):3175-99. PMC: 3173650. DOI: 10.1007/s00018-011-0783-6. View

13.

Knudsen C, Heickendorff L, Nexo E . Measurement of amino terminal propeptide of type III procollagen (PIIINP) employing the ADVIA Centaur platform. Validation, reference interval and comparison to UniQ RIA. Clin Chem Lab Med. 2013; 52(2):237-41. DOI: 10.1515/cclm-2013-0502. View

14.

Hasegawa M, Fujimoto M, Matsushita T, Hamaguchi Y, Takehara K, Sato S . Serum chemokine and cytokine levels as indicators of disease activity in patients with systemic sclerosis. Clin Rheumatol. 2010; 30(2):231-7. DOI: 10.1007/s10067-010-1610-4. View

15.

Vaglio A, Salvarani C, Buzio C . Retroperitoneal fibrosis. Lancet. 2006; 367(9506):241-51. DOI: 10.1016/S0140-6736(06)68035-5. View

16.

Biolo A, Fisch M, Balog J, Chao T, Schulze P, Ooi H . Episodes of acute heart failure syndrome are associated with increased levels of troponin and extracellular matrix markers. Circ Heart Fail. 2009; 3(1):44-50. DOI: 10.1161/CIRCHEARTFAILURE.108.844324. View

17.

Striz I, Trebichavsky I . Calprotectin - a pleiotropic molecule in acute and chronic inflammation. Physiol Res. 2004; 53(3):245-53. View

18.

Wu M, Schneider D, Mayes M, Assassi S, Arnett F, Tan F . Osteopontin in systemic sclerosis and its role in dermal fibrosis. J Invest Dermatol. 2012; 132(6):1605-14. PMC: 3365548. DOI: 10.1038/jid.2012.32. View

19.

Parums D . The spectrum of chronic periaortitis. Histopathology. 1990; 16(5):423-31. DOI: 10.1111/j.1365-2559.1990.tb01541.x. View

20.

Fan D, Takawale A, Lee J, Kassiri Z . Cardiac fibroblasts, fibrosis and extracellular matrix remodeling in heart disease. Fibrogenesis Tissue Repair. 2012; 5(1):15. PMC: 3464725. DOI: 10.1186/1755-1536-5-15. View